Gyre Therapeutics Inc.
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -34.9% | +281.7% | -59.0% | +186.5% | +0.0% | -98.1% | – | – | – | – | – | – | – | – | -89.9% | -46.1% | +127.4% | -27.8% | -22.8% | +103.1% | +6.1% | -67.5% | +5,422.4% | -33.5% | -2.4% | -12.5% | +17.6% | +9.3% | -15.3% | +0.1% | -7.2% | +1.0% | +9.4% | -20.9% | +34.8% | +2.8% | +21.7% | -39.5% | +29.2% | – | |
| – | -37.8% | +1,196.0% | +4.9% | -86.7% | +658.8% | -86.9% | +3.1% | +43.4% | +47.8% | +46.0% | -7.6% | -10.7% | -99.7% | +13,073.5% | -61.1% | -47.7% | +127.9% | -28.7% | -20.0% | +102.0% | +2.6% | -62.9% | -92.6% | +1,978.3% | -2.3% | -17.3% | -4.3% | +9.9% | +5.6% | -21.7% | -21.3% | +24.4% | +22.9% | -24.0% | +28.7% | +41.4% | +7.1% | -29.6% | +80.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -100.7% | – | – | – | – | – | – | – | – | – | -2.4% | -12.2% | +18.7% | +9.2% | -16.1% | +1.1% | -6.6% | +0.3% | +8.8% | -20.7% | +35.1% | +1.2% | +22.5% | -39.9% | +26.3% | – | |
| – | -8.4% | -33.8% | +65.0% | +11.9% | -6.4% | +5.9% | +3.1% | +43.4% | +47.8% | +46.0% | -7.6% | -10.7% | +8.7% | +22.9% | -2.7% | -5.1% | +18.5% | +17.2% | -9.8% | +32.1% | -20.4% | -40.6% | -81.2% | +248.3% | -1.0% | -57.6% | +35.4% | -15.7% | +51.8% | -52.2% | +53.8% | -17.3% | +33.8% | -16.6% | +169.8% | -71.7% | +103.8% | +39.9% | +184.0% | – | |
| – | -10.1% | +9.3% | +11.5% | -9.9% | +8.2% | +12.7% | +10.7% | -14.1% | +24.4% | +7.0% | -11.3% | -0.1% | -2.3% | +15.6% | +18.4% | -12.3% | +11.8% | +26.3% | -16.5% | +7.8% | -14.5% | -51.9% | +92.1% | +79.5% | -0.8% | -74.6% | -1.6% | -32.4% | +769.1% | -66.2% | +0.8% | +11.7% | +42.9% | -9.3% | +46.9% | -40.6% | +55.2% | +7.7% | +9.0% | – | |
| – | -9.1% | -16.0% | +36.3% | -60.5% | +157.1% | +8.8% | +5.9% | +17.9% | +40.0% | +34.5% | -8.5% | -8.2% | +5.7% | +21.5% | +1.9% | -6.9% | +16.9% | +19.3% | -11.4% | +26.6% | -19.2% | -28.2% | -61.3% | +310.3% | -2.8% | -23.9% | +35.8% | -22.3% | +549.6% | -84.6% | +16.9% | -4.2% | +28.6% | -27.6% | +63.2% | -28.6% | +60.5% | -13.3% | +34.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +0.0% | +44.8% | -25.4% | +156.6% | -817.9% | – | -59.6% | +29.8% | -84.3% | +242.8% | -198.5% | – | -98.3% | -7,895.8% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -35.7% | +333.3% | -64.9% | +645.4% | -99.0% | +71,500.0% | -86.6% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -101.9% | – | – | -6.6% | +91.1% | -996.3% | – | -51.6% | -34.9% | -80.4% | +500.4% | -134.0% | – | -100.9% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -2.7% | +54.1% | +1.5% | +76.5% | -81.0% | +264.2% | -41.2% | -28.3% | -81.1% | +343.8% | -26.5% | +155.7% | -23.2% | -147.8% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -106.5% | – | – | -17.4% | +114.6% | -2,640.4% | – | -53.2% | -68.1% | -108.8% | – | -77.8% | +503.7% | -147.7% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -5.9% | +84.5% | -142.9% | – | -51.4% | -29.8% | -74.3% | +355.9% | -123.8% | – | -92.4% | -1,461.7% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.